RAPT Therapeutics (NASDAQ: RAPT) withdraws common stock from Nasdaq listing

Rhea-AI Filing Summary

RAPT Therapeutics, Inc. notified Nasdaq Stock Market LLC of the voluntary removal of its Common Stock from listing and registration.

The notification states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing withdrawal and delisting; the filing is signed by a Nasdaq representative.

Insights

Exchange Listings Specialist

Voluntary delisting filed; Nasdaq certifies compliance with withdrawal rules.

The excerpt shows RAPT Therapeutics, Inc. submitted a Form 25 to remove its Common Stock from the Nasdaq listing, and Nasdaq states it has complied with the procedural requirements under 17 CFR 240.12d2-2.

Timing and next steps for trading status or transfer to another market are not specified in the provided excerpt; subsequent filings or exchange notices typically disclose effective dates and any transition arrangements.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38997

Issuer:	RAPT Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	561 Eccles Avenue
	South San Francisco	CALIFORNIA	94080
Telephone number:					(650) 489-9000

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-03-03	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did RAPT Therapeutics (RAPT) file a Form 25?

They filed to notify the Exchange of the voluntary removal of their Common Stock from Nasdaq listing. The form states both Nasdaq and the issuer complied with 17 CFR 240.12d2-2 rules for withdrawal and delisting procedures.

Does the Form 25 state when RAPT (RAPT) will stop trading on Nasdaq?

The provided excerpt does not state an effective delisting date. It certifies compliance with withdrawal rules; effective dates or transition details are typically disclosed in follow-up exchange notices or filings.

Who signed the Form 25 for the Nasdaq delisting of RAPT (RAPT)?

The filing excerpt is signed by a Nasdaq representative, listed as Jennifer Fainer with the title CDO Analyst. The signature certifies Nasdaq's grounds for filing under the cited rules.

Does the Form 25 indicate whether RAPT (RAPT) will register elsewhere?

The excerpt does not indicate any alternative registration or listing plans. It only certifies that Nasdaq and the issuer complied with 17 CFR 240.12d2-2 for withdrawal.

What regulatory rule governs the delisting cited in RAPT's (RAPT) Form 25?

The filing cites 17 CFR 240.12d2-2 as the governing rule. The form states Nasdaq complied with its rules and that the issuer met the requirements for voluntary withdrawal under that regulation.